MEDISCA News at Your Fingertips

MONTREAL, Q.C. (May 26, 2022) – On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio).

MONTREAL, Q.C. (January 12, 2022) – On December 9, 2021, Medisca entered into an exclusive global manufacture, supply, license and distribution agreement with Padagis (formerly, the Rx Division of Perrigo) for their ORA Product Line consisting of the following Padagis products in finished form ORA-Plus®, ORA-Sweet®, ORA-Sweet® SF, ORA-Blend®, and ORA-Blend® SF.

PLATTSBURGH, N.Y. (August 26, 2021) - MEDISCA has officially begun accepting orders for its long-awaited thyroid active pharmaceutical ingredient (thyroid API), creating a consistent supply for compounding pharmacists, prescribers and of course, their patients.

Over the last several months, MEDISCA Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.

Earlier this year MEDISCA announced that in June it would match up to $100,000 in donations to the Alliance for Pharmacy Compounding (APC) Media Fund Campaign, encouraging investments to support APC’s nationwide marketing and lobbying effort to secure compounded hormone therapy. The result was astonishing, bringing in $113,545 in investments from compounding pharmacies, which, with Medisca’s match, elevated the final amount raised in June to $213,545.

MEDISCA has finalized an exclusive distribution agreement with pharmaceutical manufacturer Sichuan Deebio Pharmaceutical Co.,Ltd to provide thyroid active pharmaceutical ingredient (API) to the compounding and non-compounding industries in the United States. This agreement will bring much-needed stability to a market that has seen inconsistent supply for several years.